abinScience | Recombinant Proteins, Antibodies & Assay Kits

Bispecific Antibodies for Research: From PD-L1×CD3 T Cell Engagers to Dual-Checkpoint Blockade

T cell engaging bispecific antibodies have moved from a niche engineering concept to a leading drug development strategy, and PD-L1×CD3 formats are extending this approach beyond hematologic targets into solid tumors. This guide introduces abinScience's newly added PD-L1×CD3 bispecific antibodies and surveys the broader 161-product bispecific catalog, including CD19/CD20×CD3 reference antibodies for approved T cell engagers and dual-checkpoint bispecifics (CTLA-4×PD-1, PD-1×VEGF) for combination blockade research.

Learn more

Canine PD-L1 Antibody: A New Comparative Oncology Tool for Veterinary Cancer Research

With the USDA's conditional licensure of the first anti-PD-1 antibody for canine mast cell tumors and melanoma, checkpoint blockade has moved from research concept to clinical reality in veterinary oncology. This guide introduces abinScience's newly added Anti-Canine PD-L1 antibody (clone 12C10E4) and surveys the broader 220-product canine checkpoint toolkit — including PD-1, CTLA-4, LAG-3, TIM-3, and HER2 reagents — supporting both spontaneous canine tumor models and comparative immuno-oncology research relevant to human therapeutic development.

Learn more

Anti-IL-17A Antibody Selection Guide: Clone Comparison for WB, ELISA, IHC & In Vivo

Not every anti-IL-17A antibody works for every application—a polyclonal built for Western blot won't perform in vivo, and an InVivoMAb-grade clone isn't optimized for IHC. This guide breaks down IL-17A antibody selection by application, comparing polyclonal antibodies for WB/IHC/ELISA; directly conjugated monoclonals for flow cytometry; InVivoMAb vs. InVivo Plus grades for neutralization studies; and reference antibodies for biosimilar benchmarking—including the newly added Bimekizumab reference antibody and mouse IL-17A recombinant protein.

Learn more

How to Set Up a Sandwich ELISA for C. difficile Toxin A Detection: A Step-by-Step Protocol

Detecting Clostridioides difficile Toxin A/tcdA reliably starts with a validated antibody pair and a properly reconstituted reference standard. This step-by-step guide walks through setting up a sandwich ELISA from plate coating through TMB development and 4-PL curve fitting, using a matched capture/detection antibody pair and a recombinant tcdA reference protein — with troubleshooting tips for background, weak standard curves, and complex sample matrices like stool eluates.

Learn more

Functional Assay Validation Guide: Choosing the Right Recombinant Protein for Bioactivity Testing

Not all recombinant proteins that pass a purity check will perform in a functional assay — the expression system used to manufacture them determines whether critical folding and glycosylation requirements are met. This guide breaks down when mammalian cell expression is essential versus when E. coli-derived protein retains full bioactivity, walks through a practical validation workflow using dose-response curves and orthogonal binding methods, and highlights abinScience's GMP-grade recombinant proteins with published ED50 data across both expression systems.

Learn more

Reference Antibodies for Biosimilar Development: How to Select and Use RUO Standards in Your Characterization Workflow

Reference Antibody, Research Use Only, Biosimilar Characterization, Anti-Drug Antibody Assay, Analytical Similarity, Functional Bioassay, oxMIF, GPC3, FOLR1, IL-6, TMPRSS6, Recombinant Monoclonal Antibody

Learn more

Semaglutide vs. Tirzepatide vs. LY3437943 A Researcher's Guide to Incretin Drug Detection and Analysis

This guide compares semaglutide, tirzepatide, and retatrutide from a research reagent perspective — covering PK ELISA kits, ADA immunogenicity assays, receptor antibodies, and biosimilar reference standards for preclinical and translational studies.

Learn more

p16INK4a (CDKN2A) Antibodies & Nanobodies — Senescence & Tumor Suppressor Research

Anti-p16INK4a/CDKN2A antibodies, VHH nanobodies, and recombinant proteins from abinScience. Polyclonal antibodies for human and mouse, nanobody SAA2259 for enhanced IHC tissue penetration, plus His-tagged and GST-tagged p16 proteins for assay controls and CDK inhibition studies.

Learn more

From GLP-1 to the Multi-Target Era: ADA 2026 Unveils New Directions in Weight-Loss Drug R&D

ADA 2026 highlights the shift from single-target GLP-1RAs to multi-target agonists (dual/triple), oral small molecules, and ultra-long-acting injectables. The latest triple-agonist data (LY3437943) show >30% weight loss, while biased oral agonists improve tolerability. Multi-target synergy, oral convenience, and neuroimaging deepen efficacy and mechanistic understanding.

Learn more

WHO Reports a Cruise Ship Hantavirus Cluster: A Multidimensional Analysis of Pathogen Biology and Pathogenesis

In May 2026, WHO reported a cruise ship cluster of fatal Hantavirus Pulmonary Syndrome (HPS) cases caused by Andes virus (ANDV), This article provides a multidimensional analysis of hantavirus, covering pathogenic characteristics (genome organization into L, M, S segments), transmission routes, molecular mechanisms of vascular endothelial dysfunction, cytokine storm, and clinical syndromes (HFRS and HPS).

Learn more

Kent Meningococcal Outbreak 2026: Invasive MenB Disease Mechanisms and Vaccine Breakthroughs

Latest update on the 2026 Kent, UK MenB meningitis outbreak (27 cases, 2 deaths). In-depth look at Neisseria meningitidis pathogenesis, intracellular escape, blood-brain barrier crossing, key antigens (FHbp, NHBA, NadA), and 2025–2026 pentavalent MenABCWY vaccine advances (PENBRAYA, PENMENVY).

Learn more

Biosimilars Enter a New Growth Phase: Biologics R&D Trends and Research Opportunities in 2026

Biosimilars are entering a new deterministic growth cycle in 2026, fueled by the intensive patent expiration of global blockbuster biologics and the continuous improvement of worldwide regulatory systems. This article outlines core 2026 biologics R&D trends, identifies autoimmune diseases as the key R&D track, details four core immune regulatory pathways and blockbuster candidates expected to be approved in 2026, and elaborates the industrial, clinical and research value of biosimilar

Learn more

Recombinant Proteins

Antibodies

Assay Kits

Browse by products

Featured content

About abinScience

News

Quick access

Contact Us